Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
Leendert Trouw benoemd tot hoogleraar Complementbiologie en -therapie
feb 2023 | Immuuntherapie, RA, Tuberculose